Lead, at low levels, accelerates arteriolopathy and tubulointerstitial injury in chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 4, 2007, Pages

  Roncal, Carlos ^a   Mu, Wei ^a   Reungjui, Sirirat ^a   Kim, Kyung Mee ^a   Henderson, George N ^a   Ouyang, Xiaosen ^a   Nakagawa, Takahiko ^a   Johnson, Richard J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Arteriolosclerosis; Hypertension; Interstitial inflammation; Uric acid

Indexed keywords

LEAD; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTERY DISEASE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LEAD BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 35148883613     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00216.2007     Document Type: Article

References (48)

1. Attri J, Dhawan V, Mahmood S, Pandhi P, Parwana HK, Nath R. Effect of vitamin C supplementation on oxidative DNA damage in an experimental model of lead-induced hypertension. Ann Nutr Metab 47: 294-301, 2003.
2. Beevers DG, Erskine E, Robertson M, Beattie AD, Campbell BC, Goldberg A, Moore Hawthorne VM MR. Blood-lead hypertension. Lancet 2: 1198-1202, 1976.
3. Bener A, Obineche E, Gillett M, Pasha MAH, Bishawi B. Association between blood levels of lead, blood pressure, and risk of diabetes and heart disease in workers. Int Arch Occup Environ Health 74: 375-378, 2001.
4. Chisolm JJ, Harrison HC, Eberlein WR, Harrison HE. Amino-aciduria, hypophosphatemjia, and rickets in lead poisoning. Am J Dis Child 89: 159-168, 1955.
5. Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L. Lead-induced hypertension. III. Increased hydroxyl radical production. Am J Hypertens 14: 169-173, 2001.
6. Ehrlich R, Robins T, Jordaan E, Miller S, Mbuli S, Selby P, Wynchank S, Cantrell A, De Broe M, D'Haese P, Todd A, Landrigan P. Lead absorption and renal dysfunction in a South African battery factory. Occup Environ Med 55: 453-460, 1998.
7. Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: a review of the epidemiological evidence. Kidney Int 70: 2074-2084, 2006.
8. Emmerson BT, Microsch W, Douglas JB. The relative contributions of tubular reabsorption and secretion to urate excretion in lead nephropathy. Aust NZ J Med 4: 353-362, 1971.
9. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension. Interplay of nitric oxide and reactive oxygen species. Hypertension 30: 1487-1492, 1997.
10. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76: 47-56, 1984.
11. Hernandez-Serrato MI, Fortoul TI, Rojas-Martinez R, Mendoza-Alvarado LR, Canales-Trevino L, Bochichio-Riccardelli T, Avila-Costa MR, Olaiz-Fernandez G. Lead blood concentrations and renal function evaluation: study in an exposed Mexican population. Environ Res 100: 227-231, 2006.
12. Huchard H. Arteriolosclerosis: including its cardiac form. JAMA 53: 1129, 1909.
13. Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 124: 65-76, 1978.
14. Johnson G. The anatomy of Bright's disease: the arterio-capillary fibrosis of Sir William Gull and Dr Sutton. Brit Med J I: 604-605, 1872.
15. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346: 913-923, 2002.
16. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 18: 431-440, 2005.
17. Johnson RJ, Segal MS, Srinivas TR, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Herrera-Acosta J. Essential hypertension, progressive renal disease and uric acid: a pathogenetic link? J Am Soc Nephrol 16: 1909-1919, 2005.
18. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002.
19. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase, and cyclooxygenase-2. Hypertension 41: 1287-1293, 2003.
20. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739-1742, 2005.
21. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348: 277-286, 2003.
22. Lin JL, Tan DT, Ho HH, Yu CC. Environmental lead exposure and urate excretion in the general population. Am J Med 113: 563-568, 2002.
23. Lin JL, Yu CC, Lin-tan DT, Ho HH. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int 60: 266-271, 2001.
24. Mahaffey KR, Capar SG, Gladen BC, Fowler BA. Concurrent exposure to lead, cadmium, and arsenic. J Lab Clin Med 98: 463-481, 1981.
25. Mahomed FA. The etiology of Bright's disease and the prealbuminuric state. Med Chir Trans 39: 197-228, 1874.
26. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001.
27. Mu W, Ouyang X, Agarwal A, Long DA, Cruz PE, Roncal CA, Glushakova OY, Chiodo VA, Atkinson MA, Hauswirth WW, Flotte TR, Rodriguez-Iturbe B, Johnson RJ. Interleukin-10 suppresses chemokines, inflammation and fibrosis in a model of chronic renal disease. J Am Soc Nephrol 16: 3651-3660, 2005.
28. Munter P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 63: 1044-1050, 2003.
29. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 66: 2329-2360, 2004.
30. Padilla F, Shapiro AP, Jensen WN. Effect of chronic lead intoxication on blood pressure in the rat. Am J Med Sci 258: 359-365, 1969.
31. Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 33: 2314-2316, 1987.
32. Rodriguez-Iturbe B, Sindhu RK, Quiroz Y, Vaziri ND. Chronic exposure to low doses of lead results in renal infiltration of immune cells, NF-kappaB activation, and overexpression of tubulointerstitial angiotensin II. Antioxid Redox Signal 7: 1269-1274, 2005.
33. Roncal C, Mu W, Croker B, Reunjui S, Ouyang X, Tabah-Fische I, Johnson RJ, Ejaz AA. Effect of an elevated uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 292: F116-F122, 2007.
34. Sánchez-Fructuoso AI, Blanco J, Cano M, Ortega L, Arroyo M, Fernández C, Prats D, Barrientos A. Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetracetate. Am J Kid Dis 40: 59-67, 2002.
35. Sánchez-Fructuoso AI, Torralbo A, Arroyo M, Luque M, Ruilope LM, Santos JL, Cruceyra A, Barrientos A. Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transpl 11: 1775-1780, 1996.
36. Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, Soto V, Ávila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 292: F423-F429, 2007.
37. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: The Normative Aging Study. J Rheumatol 27: 1708-1712, 2000.
38. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51-59, 2006.
39. Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 27: 435-440, 2007.
40. Trachtman H, Valderrama E, Futterweit S. Nephrotoxicity of allopurinol is enhanced in experimental hypertension. Hypertension 17: 194-202, 1991.
41. Victery W. Evidence for effects of chronic lead exposure on blood pressure in experimental animals: an overview. Environ Health Perspect 78: 71-76, 1988.
42. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360, 2002.
43. Watts RWE, Scott JT, Chalmers RA, Bitensky L, Chayen J. Microscopic studies on skeletal muscle in gout patients treated with allopurinol. Quart J Med 40: 1-14, 1971.
44. Weaver VM, Lee BK, Todd AC, Jaar BG, Ahn KD, Wen J, Shi W, Parsons PJ, Schwartz BS. Associations of patella lead and other lead biomarkers with renal function in lead workers. J Occup Environ Med 47: 235-243, 2005.
45. Wedeen RP, Maesaka JK, Weiner B, Lipat GA, Lyons MM, Vitale LF, Joselow MM. Occupational lead nephropathy. Am J Med 59: 630-641, 1975.
46. Wedeen RP, Mallik DK, Batuman V. Detection and treatment of occupational lead nephropathy. Arch Int Med 139: 53-57, 1979.
47. Wilson VK, Thomson ML, Dent CE. Amino-aciduria in lead poisoning. A case in childhood. Lancet 2: 66-68, 1953.
48. Yu CC, Lin JL, Lin-tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 15: 1016-1022, 2004.